Combination treatment for peripheral T-cell lymphoma that has returned
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs, chidamide and golidocitinib, for peripheral T-cell lymphoma that has come back or not responded to earlier treatments. The goal is to see if this combination can help shrink or control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old and have a confirmed diagnosis of peripheral T-cell lymphoma (a type of blood cancer).
- Your lymphoma has either not responded to prior treatment or has come back after treatment. You must have had 1 to 3 prior treatments.
- You have at least one measurable tumor (larger than about half an inch in a lymph node or smaller in other areas).
- Your overall health is reasonably good (able to care for yourself, but may not be fully active).
- Your blood counts and organ function are within certain limits (like white blood cells, platelets, and kidney/liver tests).
- You have not had chemotherapy, radiation, or a stem cell transplant within 3 weeks before starting, and you have not taken certain medications (like JAK inhibitors or HDAC inhibitors) that might interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This trial tests a combination of two targeted drugs, Chidamide and Duvalisib, for people with peripheral T-cell lymphoma or NK/T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this drug combination can help shrink or control the lymphoma.
This trial tests a combination treatment for peripheral T-cell lymphoma, a type of blood cancer. It may help patients who cannot tolerate standard chemotherapy or whose disease has come back.
This study tests a new combination therapy with a drug called tazemetostat for people with peripheral T-cell lymphoma that has relapsed (come back) or is refractory (did not respond to previous treatment). The goal is to see if this combination can help control the lymphoma.
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.